DDInter1140 DDInter1376
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Mefloquine {u} (Compound) binds {v} (Gene) ACHE
Mefloquine {u} (Compound) upregulates {v} (Gene) DDIT4
Mefloquine {u} (Compound) downregulates {v} (Gene) RRP12
Mefloquine {u} (Compound) causes {v} (Side Effect) Leukocytosis
Mefloquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metoclopramide
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Ibutilide
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Mefloquine (Compound) resembles Flecainide (Compound)
Mefloquine (Compound) binds ACHE (Gene)
Mefloquine (Compound) upregulates DDIT4 (Gene)
Mefloquine (Compound) downregulates RRP12 (Gene)
Mefloquine (Compound) causes Leukocytosis (Side Effect)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid
Mefloquine may lead to a major life threatening interaction when taken with Ibutilide
Mefloquine may lead to a major life threatening interaction when taken with Pimozide